Skip to main content

Table 4 Study-based age- and gender-standardized prevalence estimates for subjective cognitive decline (SCD; last column) and cumulative frequency estimates for the stepwise application of SCD operationalization criteria according to quantitative harmonization/Item Response Theory (IRT) modeling

From: Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study

Study

SCD operationalization criteria

Criterion 1

Endorsement of a self-experienced decline in cognitive capacity without objective cognitive impairment

+ Criterion 2

Intact functional ability

+ Criterion 3

No major depression

+ Criterion 4

No anxiety disorder

Prevalence estimates in % (95%CI)

ActiveAging

27.97 (21.43–34.51)

25.80 (19.40–32.20)

25.73 (19.36–32.10)

N/A

CFAS

23.44 (21.77–25.12)

21.59 (19.91–23.26)

17.78 (16.36–19.20)

9.60 (8.63–10.58)

EAS

50.41 (45.20–55.62)

46.06 (41.06–51.06)

38.71 (34.07–43.34)

25.91 (19.33–32.48)

EPIDEMCA

56.28 (54.18–58.38)

53.02 (50.83–55.21)

30.64 (28.51–32.77)

28.41 (26.38–30.44)

ESPRIT

31.26 (29.34–33.18)

28.76 (26.89–30.63)

23.97 (22.20–25.74)

18.94 (17.36–20.51)

Invece.Ab

14.61 (11.64–17.58)

14.03 (10.90–17.17)

12.32 (9.44–15.20)

10.77 (8.28–13.26)

KLOSCAD

55.51 (54.09–56.92)

50.55 (49.10–52.00)

36.01 (34.62–37.40)

35.97 (34.62–37.31)

LEILA75+

12.89 (11.66–14.13)

11.71 (10.49–12.94)

9.81 (8.65–10.97)

N/A

LRGS-TUA

51.23 (48.15–54.31)

47.40 (44.32–50.47)

46.84 (43.80–49.87)

N/A

MAAS

65.26 (60.32–70.20)

60.52 (55.34–65.69)

54.97 (49.43–60.51)

52.70 (47.43–57.98)

MoVIES

29.39 (26.97–31.81)

27.20 (24.83–29.57)

23.87 (21.59–26.15)

N/A

PATH

11.68 (10.50–12.86)

10.76 (9.62–11.90)

9.63 (8.54–10.73)

7.83 (6.80–8.87)

SGS

18.47 (16.81–20.12)

16.51 (14.93–18.09)

10.24 (8.93–11.54)

9.91 (8.64–11.18)

SLASII

25.48 (23.37–27.59)

22.87 (20.83–24.91)

22.17 (20.16–24.18)

21.18 (19.31–23.05)

SydneyMAS

45.81 (43.41–46.39)

42.72 (40.48–44.95)

35.87 (33.55–38.19)

29.88 (27.54–32.22)

ZARADEMP

44.69 (42.99–46.39)

42.04 (40.32–43.77)

30.64 (28.51–32.77)

28.12 (26.50–29.74)

Total*

37.32 (36.85–37.79)

34.49 (34.02–34.97)

27.75 (27.31–28.20)

25.60 (25.06–26.14)

  1. 95%CI 95% confidence interval, N/A not available
  2. *Unstandardized